For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- PRESS SEMINARS
June 17, 2002
- Gemcitabine, Carboplatin Combination Useful for NSCLC: ASCO
June 17, 2002
- Mr Wager of Aventis Behring Points Out Problems with Proposed Blood Law
June 17, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 17, 2002
- Preventive Effects of Evista on Bone Fractures in Osteoporosis Reported
June 17, 2002
- We Are at Exciting Crossroads in History: Mr Hassan at PhRMA
June 17, 2002
- Matsumotokiyoshi: Record-high Sales of \256 Bil., Profits of \6.6 Bil. Posted
June 17, 2002
- Eli Lilly's Teriparatide Effective against Severe Osteoporosis
June 17, 2002
- 94 Drugs in Development for Children: PhRMA Survey
June 17, 2002
- BULLETIN
June 17, 2002
- Ohki: Consolidated Sales Increase by 4.1% to \69.7 Bil.
June 17, 2002
- Clinical Trial Results for Eli Lilly's New ED Drug Reported
June 17, 2002
- GSK Publishes Review of Its Commitment to Society, Environment
June 17, 2002
- BUSINESS NEWS IN BRIEF
June 17, 2002
- OTC NEW IN BRIEF
June 17, 2002
- Taxotere-based Chemotherapy Improves Breast Cancer Survival
June 17, 2002
- Lilly's Drotrecogin Prolongs Survival of Severe Sepsis Patients
June 17, 2002
- Website NEWS
June 17, 2002
- Hitachi Medical to Commercialize Regenerative Tooth
June 17, 2002
- Zoledronate Effective against Bone Metastases from Prostate Cancer
June 17, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…